Article
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
Cell cycle (Georgetown, Tex.) - 15 Jun 2008
Shell Scott A, Lyass Ljuba, Trusk Patricia B, Pry Karen J, Wappel Robert L, Bacus Sarah S
Abstract excerpt
ErbB2 targeted therapies represent an attractive strategy in breast cancer. Herceptin, an anti-ErbB2 monoclonal antibody, is an approved treatment for patients with ErbB2-overexpressing breast cancers. ErbB2 signaling can also be blocked using small molecule tyrosine kinase inhibitors, like Lapatinib, that compete with ATP for binding at the ErbB2 catalytic kinase domain. The principal adverse event attributable...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.